The Zika Virus Individual Participant Data Consortium

31 October, 2020

Dear all, greetings from Honduras.

I am sharing a recent publication about a global initiative to estimate the effects of exposure to Zika virus during pregnancy on adverse fetal, infant, and child health outcomes: The Zika Virus Individual Participant Data Consortium.

Alger J, Ximenes RAA, Avelino-Silva VI, Bardají A, Hernan Becerra Mojica C, Benedetti A, et al. The Zika Virus Individual Participant Data Consortium: A Global Initiative to Estimate the Effects of Exposure to Zika Virus during Pregnancy on Adverse Fetal, Infant, and Child Health Outcomes. Tropical Medicine and Infectious Disease 2020; 5: 0152.

Here is the abstract. The full article is available at https://pubmed.ncbi.nlm.nih.gov/33007828/

Of remark, in Figure 1 there is an image demonstrating the distribution of monthly Zika virus (ZIKV) cases and Zika virus-related longitudinal studies of pregnant women and their infants and children. Each of the 42 colored circles represents a participating study with color corresponding to country/region and circle size corresponding to the number of pregnant women enrolled in the study. The horizontal colored lines indicate the time period during which a participating study recruited pregnant women. Honduras has one of the largest cohorts, that started in the peak of Zika transmission and that is still enrolling patients.

Abstract: This commentary describes the creation of the Zika Virus Individual Participant Data Consortium, a global collaboration to address outstanding questions in Zika virus (ZIKV) epidemiology through conducting an individual participant data meta-analysis (IPD-MA). The aims of the IPD-MA are to (1) estimate the absolute and relative risks of miscarriage, fetal loss, and short- and long-term sequelae of fetal exposure; (2) identify and quantify the relative importance of di_erent sources of heterogeneity (e.g., immune profiles, concurrent flavivirus infection) for the risk of adverse fetal, infant, and child outcomes among infants exposed to ZIKV in utero; and (3) develop and validate a prognostic model for the early identification of high-risk pregnancies and inform communication between health care providers and their patients and public health interventions (e.g., vector control strategies, antenatal care, and family planning programs). By leveraging data from a diversity of populations across the world, the IPD-MA will provide a more precise estimate of the risk of adverse ZIKV-related outcomes within clinically relevant subgroups and a quantitative assessment of the generalizability of these estimates across populations and settings. The ZIKV IPD Consortium effort is indicative of the growing recognition that data sharing is a central component of global health security and outbreak response.

Best regards

J

--

Jackeline Alger, MD, PhD

Servicio de Parasitologia

Departamento de Laboratorio Clinico

Hospital Escuela Universitario

Tegucigalpa, HONDURAS

HIFA profile: Jackeline Alger works in the Parasitology Service, Department of Clinical Laboratories, Hospital Escuela Universitario, and at the Faculty of Medical Sciences, Universidad Nacional Autonoma de Honduras, Tegucigalpa, Honduras. She is a Country Representative for HIFA and CHIFA and is the 2-time holder of HIFA Country Representative of the Year Award 2015 and 2018. http://www.hifa.org/people/country-representatives/map

http://www.hifa.org/support/members/jackeline

Email: jackelinealger AT gmail.com